Compare iShares MBS ETF (MBB) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MBS ETF vs Natera Inc. Common Stock — how do they compare? iShares MBS ETF trades at $89.99 (market cap $35.76B), while Natera Inc. Common Stock trades at $391.06 (market cap $57.03B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MBS ETF for 97 Days and Natera Inc. Common Stock for 0 Days on average.
| MBB | NTRA | |
|---|---|---|
Market Cap | $35.76B | $57.03B |
Volume | 19,694,940 | 1,131,157 |
Sector | Fixed Income | Health |
52-Week High | $96.91 | $425.64 |
52-Week Low | $89.09 | $179.42 |
Typical Hold Time | 97 Days | 0 Days |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MBB (iShares MBS ETF) trades at $89.97 with minimal daily movement (+0.16%). The technical outlook is bearish with moving averages and oscillators signaling caution, though the stock shows strong institutional interest despite recent short interest growth. Recent news highlights Norway's sovereign wealth fund rotating into mortgage-backed securities, providing sector validation.
The ETF faces headwinds from rising intermediate-term rates and convexity risk, limiting upside potential. While dividend payments provide income, the bearish technical setup and interest rate sensitivity suggest cautious positioning. Institutional accumulation contrasts with growing short interest, creating mixed signals for investors.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
